Pharmacogenomics

Diatech Pharmacogenetics Announces New Collaboration to Advance Precision Testing in Oncology

Retrieved on: 
Tuesday, June 20, 2023
Oncology, Health, Biometrics, Other Health, General Health, Pharmaceutical, Real-time polymerase chain reaction, Neoplasm, Bone marrow, Pharmacogenomics, Cancer, Bladder cancer, Janssen, Patient, Medicine, IVD, Growth, PCR, Medical imaging, EU, WHO model list of essential in vitro diagnostics

Diatech Pharmacogenetics (“Diatech”) has established a collaboration agreement with Janssen Pharmaceutica NV with the aim of improving access to precision medicine for patients with bladder cancer.

Key Points: 
  • Diatech Pharmacogenetics (“Diatech”) has established a collaboration agreement with Janssen Pharmaceutica NV with the aim of improving access to precision medicine for patients with bladder cancer.
  • As one of Europe's leading precision medicine companies, Diatech Pharmacogenetics researches and manufactures In Vitro Diagnostic (IVD) tests in oncology for various types of solid tumours and blood cancers.
  • Diatech Pharmacogenetics is working on the development of a new molecular test dedicated to bladder cancer, with the aim to enable patients access precision drug treatments, based on their individual molecular profile.
  • Diatech Pharmacogenetics is a leading Italian company in the development, production and commercialization of molecular diagnostic tools for precision oncology medicine.

Retinalgenix Technologies, Inc. Expands Team to Hasten the Launch of DNA/GPS

Retrieved on: 
Wednesday, June 7, 2023
Retina, DNA, CT, Diabetes, HIPPA, Pharmacogenomics, Stroke, OTCQB, PET, Intelligence, Paratriathlon, Risk, Science, MRI, Alzheimer's disease, Dementia, Parkinson's disease, Data analysis, Hospital, Systemic disease, MD, Patient, Laboratory, Deep learning, Genetic testing, Neurological disorder, Diagnosis, HIPAA, Kidney disease, Pharmaceutical industry, Television, Medical imaging

The application is expected to allow patients to obtain their genetic systemic bio-markers privately, discreetly, and confidentially.

Key Points: 
  • The application is expected to allow patients to obtain their genetic systemic bio-markers privately, discreetly, and confidentially.
  • His experience in the management of pharmacogenetics and imaging in a HIPPA-compliant database will be a great asset to RetinalGeniX,” said Dr. Larry Perich, Lead Investigator and Co-developer of DNA/GPS.
  • Owen has integrated his skill set by optimizing cloud-based offerings and designing top-notch security solutions.
  • “We are thrilled to announce the addition of Owen Watson to our team.

Standard BioTools Appoints Jeffrey Black as Chief Financial Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Monday, May 15, 2023
Employment, University, Senior, EY, Boston Scientific, Pharmacogenomics, Special, Proteomics, Standard BioTools, Standard, Accounting, Acquisition, SAN, Growth, Health, RSU, Management

SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced the appointment of Jeffrey Black as Senior Vice President and Chief Financial Officer effective today. Black will lead Standard BioTools’ finance, accounting and investor relations functions, reporting to Michael Egholm, Ph.D., President and Chief Executive Officer. Vikram Jog will remain at the company for a period as Special Advisor to the CEO to ensure an effective transition.

Key Points: 
  • Black will lead Standard BioTools’ finance, accounting and investor relations functions, reporting to Michael Egholm, Ph.D., President and Chief Executive Officer.
  • “We are excited to welcome Jeff to the Standard BioTools executive leadership team.
  • Previously, Mr. Black was Chief Financial Officer of Applied Proteomics, Inc., a proteomics-based diagnostics company, and as Chief Financial Officer of AltheaDx, Inc., a pharmacogenetics diagnostics company.
  • In accordance with Nasdaq Listing Rule 5635(c)(4), a majority of the independent directors serving on the company’s Board of Directors approved Mr. Black’s inducement awards.

The Inner Circle Acknowledges, James G. Krueger MD, Ph.D., as a Pinnacle Life Healthcare Provider for his contributions as a Dermatologist

Retrieved on: 
Friday, May 5, 2023
COPSS Distinguished Achievement Award and Lectureship, Tissue, Bachelor, ABD, Therapy, Weill Cornell Medicine, Doctor of Philosophy, Education, Internal medicine, Rockefeller University, Head, Professional, Pharmacogenomics, Research fellow, Skin, Psoriasis, T helper 17 cell, Medicine, Research, Gene expression, Multimedia, Inflammation, Princeton University, Rheumatoid arthritis, Science, Trial of the century, Inflammatory bowel disease, Inner circle, American Board of Commissioners for Foreign Missions, Cell biology, Patient, Hidradenitis suppurativa, Physician, American Board of Dermatology, Immune system, Knowledge, Diagnosis, Innovation, Laboratory, Vaccine, Pharmaceutical industry, Dermatology, Virology

NEW YORK, May 4, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, James G. Krueger MD, Ph.D., is acknowledged as a Pinnacle Life Healthcare Provider for his contributions as a Dermatologist.

Key Points: 
  • NEW YORK, May 4, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, James G. Krueger MD, Ph.D., is acknowledged as a Pinnacle Life Healthcare Provider for his contributions as a Dermatologist.
  • Dr. Krueger pursued higher education at Princeton University where he earned a Bachelor's degree from Princeton University.
  • He received a medical degree from Cornell University Medical College and completed an internship in internal medicine and a residency in dermatology.
  • According to Dr. Krueger, the laboratory at The Rockefeller University Hospital conducts clinical research on patients with psoriasis vulgaris.

Avalon GloboCare Reports Laboratory Services MSO Revenue of $14.7 Million and Net Income of $6.3 Million in 2022

Retrieved on: 
Thursday, April 27, 2023
Avalon, Pharmacogenomics, Pathology, STAT, National Health Laboratory Service, LSM, Laboratory, Toxicology, Genetic testing, Medical device

In February 2023, Avalon acquired a 40% interest in LSM, a premier clinical diagnostics and reference laboratory.

Key Points: 
  • In February 2023, Avalon acquired a 40% interest in LSM, a premier clinical diagnostics and reference laboratory.
  • “We are pleased to report strong financial results and profitability for LSM in 2022, which we believe is further validation of our strategic investment,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare.
  • “LSM offers an extensive test menu, from general bloodwork to anatomic pathology, urine toxicology, pharmacogenomics (PGx) testing and more, with quick turnaround times.
  • Specific capabilities include STAT blood testing, qualitative drug screening, genetic testing, urinary testing, sexually transmitted disease testing and more.

Diatech Pharmacogenetics Announces Investment from TA to Fuel Strategic Growth Initiatives

Retrieved on: 
Wednesday, April 26, 2023
Oncology, Professional Services, Health, Genetics, Finance, Pharmaceutical, Biotechnology, Partnership, Pharmacogenomics, TA, Multimedia, TA Associates, Cancer, Medicine, Diagnosis, Growth, Medical device, EU

Diatech Pharmacogenetics (“Diatech” or “the Company”), a leader in pharmacogenetics and cancer precision medicine diagnostics, today announced that TA Associates (“TA”), a leading global private equity firm, has signed a definitive agreement to make a strategic growth investment in the Company.

Key Points: 
  • Diatech Pharmacogenetics (“Diatech” or “the Company”), a leader in pharmacogenetics and cancer precision medicine diagnostics, today announced that TA Associates (“TA”), a leading global private equity firm, has signed a definitive agreement to make a strategic growth investment in the Company.
  • Diatech’s founder and management team will retain majority ownership of the Company, partnering closely with TA.
  • “We are excited to welcome TA on this journey with us amid a period of great advancement in precision medicine,” said Fabio Biondi, Founder and President of Diatech.
  • “TA offers extensive operational experience and a wide global network that will be critical as we strive to accelerate our international growth and product innovation.

Namida Wins Top Intelligent Diagnostics Award for Auria® at Prestigious 2023 Edison Awards™ Honors

Retrieved on: 
Tuesday, April 25, 2023
Research, Women, Biotechnology, Health, Consumer, General Health, Other Science, Science, Oncology, Medicine, Education, Marketing, Lab, CSO, Tears, Cancer, Woman, Genentech, 37.5°C no Namida, Pharmacogenomics, Thomas Edison, GRAIL, Gold, Engineering, General Motors, Edison Awards, Pharmaceutical industry

Namida Lab's innovative biological breast cancer screening technology, Auria®, has been awarded the prestigious Gold prize for Intelligent Diagnostics at the 36th annual Edison Awards in Fort Myers, Florida.

Key Points: 
  • Namida Lab's innovative biological breast cancer screening technology, Auria®, has been awarded the prestigious Gold prize for Intelligent Diagnostics at the 36th annual Edison Awards in Fort Myers, Florida.
  • Namida Founder and CEO Omid Moghadam and CSO Dr. Anna Daily, Ph.D., inventor of Auria, accepted the award on behalf of the company.
  • The Edison Awards™, named after the American inventor Thomas Alva Edison, celebrates the best in product and service development, marketing, design, and innovation.
  • With the top prize at the 2023 Edison Awards, the company is well-positioned to continue fighting cancer and saving lives through early detection.

Reviva Pharmaceuticals to Host Key Opinion Leader Event on Brilaroxazine (RP5063) in Phase 3 Clinical Trials for Schizophrenia

Retrieved on: 
Tuesday, April 25, 2023
Molecule, PD, Pharmacogenomics, Drug, Patient, Environment, Neurology, Clinical, BCPP, University, CSO, Allodynia, Parexel, DSM-IV codes, Capsaicin, Magnetic resonance, MRS, RP5063, UV, NGF, FIH, CSF, Serotonin, ChromeOS, Safety, Public key certificate, FCCP, Research, Neurodegenerative disease, KOL, Central nervous system, Drug development, Doctor of Pharmacy, UT, PET, CNS, Bipolar disorder, AD, APEX, Pharmacology, Pharmaceutical industry, Schizophrenia, Psychopharmacology, Depression, Psychiatry, Pharmacy

He will look at brilaroxazine, a next-generation serotonin-dopamine modulator, and its potential as a treatment solution for schizophrenia.

Key Points: 
  • He will look at brilaroxazine, a next-generation serotonin-dopamine modulator, and its potential as a treatment solution for schizophrenia.
  • The Reviva leadership team will provide an overview of the efficacy and safety data generated in the clinical trials completed to date and an update on ongoing RECOVER Phase 3 trial evaluating brilaroxazine in patients with acute schizophrenia.
  • Brilaroxazine is a new chemical entity with broad therapeutic potential in neuropsychiatric and inflammatory conditions arising from underlying dysfunction in serotonin and dopamine signaling.
  • Dr. Ereshefsky’s unique perspective as a clinical scientist (clinical psychiatric pharmacist and psychopharmacologist) helps to guide drug development from preclinical to late Phase.

Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs

Retrieved on: 
Monday, April 24, 2023
IPN, Medicine, Endocrinology, Medical Affairs Bureau, Emergency medicine, ADR, Internal medicine, Genetics, Pharmacogenomics, EVP, Cardiovascular disease, ELT, Eli Lilly, Good Samaritan Regional Medical Center (Oregon), Patient, DSM-IV codes, Physician, Scientific communication, Patient safety, Medical device, Pharmaceutical industry, Ipsen, Euronext, Sanofi

Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs

Key Points: 
  • Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs
    PARIS, FRANCE, 24 April 2023 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Sandra Silvestri, M.D., Ph.D., as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs, effective 5 May 2023.
  • Sandra brings years of extensive medical experience in the global biopharmaceutical industry and joins Ipsen after spending eight years at Sanofi.
  • Since 2020, she has served as Senior Vice President and Chief Medical Officer of the General Medicines Global Business Unit, and Global Head of Medical Affairs Capabilities Centre of Excellence and Medical Hub, where she was responsible for worldwide medical affairs strategy and execution.
  • Steven Hildemann, M.D., Ph.D., who served as Ipsen’s Chief Medical Officer for three years and successfully led a deep transformation of Global Medical Affairs and Patient Safety, will leave Ipsen to pursue other opportunities after handing over to Sandra.

Genetic Testing Market to Reach $28.24 Billion by 2030 - Market Size, Share, Forecasts, & Trends Analysis Report by Meticulous Research®

Retrieved on: 
Monday, March 20, 2023
Glaucoma, DNA, Ventricular septal defect, Prevalence, Impact, Viral Research and Diagnostic Laboratories, Parent, Hospital, Pharmacogenomics, COVID-19, Cancer, Down syndrome, Genetic testing, Diagnosis, Genomics, Hemoglobinopathy, Disorder, Government, PerkinElmer, Fragile X syndrome, MUFG Americas Holdings Corporation, Thermo Fisher Scientific, Patient, Laboratory, Risk, Developed country, Preimplantation genetic diagnosis, Investment, Labcorp, Consumables, Cystic fibrosis, Carrier, Hospital Clinic Manuel Quintela, Association for Molecular Pathology v. Myriad Genetics, Inc., Rare, Illumina, Inc., Geography, Pharmaceutical industry, Dietary supplement, Chromosome, Prenatal development

Genetic testing is done to look at changes in the DNA, sometimes called variants or mutations, that can lead to chronic diseases.

Key Points: 
  • Genetic testing is done to look at changes in the DNA, sometimes called variants or mutations, that can lead to chronic diseases.
  • Genetic testing is performed for different reasons, including pre-symptomatic and predictive testing, pharmacogenetics, diagnostic testing, carrier testing, prenatal testing, preimplantation testing, and newborn screening.
  • Genetic testing has applications in different areas of healthcare and has various advantages, such as determining the likelihood of parents passing the genetic mutation to their offspring.
  • Quick Buy – Genetic Testing Market Research Report: https://www.meticulousresearch.com/Checkout/33822956
    Based on end user, in 2023, the hospitals & clinics segment is expected to account for the largest share of this market.